Výsledky vyhledávání - "Kiyofumi Sasai"

Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial

Autor: Takeshi Inoue, Tadayuki Kitagawa, Kiyofumi Sasai, Akira Nishimura

Publikováno v: Psychiatry and Clinical Neurosciences. 72:103-115

Aim Safety and efficacy of vortioxetine (5-20 mg/day) in Japanese patients with major depressive disorder were evaluated in two phase 3 studies consisting of a short-term, 8-week, placebo-controlled, double-blind study followed by a long-term, 52-wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19a87847ee9d886ff7e970173a7cbb52
https://doi.org/10.1111/pcn.12623

Zobrazit plný text záznamu

Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

Autor: Yutaka Aritomi, Atul R. Mahableshwarkar, Kiyofumi Sasai, Akira Nishimura, Tadayuki Kitagawa

Publikováno v: Psychiatry and Clinical Neurosciences. 72:64-72

Aim This study assessed the efficacy and safety of vortioxetine in adults with major depressive disorder. Methods In this double-blind, placebo-controlled study, 600 patients with major depressive disorder were randomly assigned (1:1:1:1) to receive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::788e013c23378b690396604cebfda172
https://doi.org/10.1111/pcn.12565

Zobrazit plný text záznamu

Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder

Autor: Tadayuki Kitagawa, Takeshi Inoue, Isao Inada, Akira Nishimura, Kiyofumi Sasai

Publikováno v: Psychiatry and Clinical Neurosciences

AIM The burden of major depressive disorder (MDD) in Japan is high. This study aimed to evaluate the efficacy and safety of the multimodal antidepressant vortioxetine in Japanese patients with MDD. METHODS Japanese patients aged 20-75 years with recu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb2a6f994a5570bf9c05f765f790a23
https://pubmed.ncbi.nlm.nih.gov/32175646

Zobrazit plný text záznamu

A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Autor: Tsukasa Fujimoto, Kiyofumi Sasai, Shinzaburo Noguchi, Junichi Kurebayashi, Hirotaka Iwase, Eiichi Shiba, Hiroko Yamashita, Yasuo Ohashi

Publikováno v: Breast Cancer (Tokyo, Japan)

Background Luteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist, leupror

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85920dbddf0b820f1560fe2acbd59fff
https://doi.org/10.1007/s12282-015-0593-z

Zobrazit plný text záznamu

Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial

Autor: Takeshi, Inoue, Akira, Nishimura, Kiyofumi, Sasai, Tadayuki, Kitagawa

Publikováno v: Psychiatry and clinical neurosciences. 72(2)

Safety and efficacy of vortioxetine (5-20 mg/day) in Japanese patients with major depressive disorder were evaluated in two phase 3 studies consisting of a short-term, 8-week, placebo-controlled, double-blind study followed by a long-term, 52-week, o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::629313d4d0b1b79b97567f12238be8a8
https://pubmed.ncbi.nlm.nih.gov/29160598

Zobrazit plný text záznamu

Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

Autor: Akira, Nishimura, Yutaka, Aritomi, Kiyofumi, Sasai, Tadayuki, Kitagawa, Atul R, Mahableshwarkar

Publikováno v: Psychiatry and clinical neurosciences. 72(2)

This study assessed the efficacy and safety of vortioxetine in adults with major depressive disorder.In this double-blind, placebo-controlled study, 600 patients with major depressive disorder were randomly assigned (1:1:1:1) to receive vortioxetine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ce3b77a10b73b10c122bcf68001cc93f
https://pubmed.ncbi.nlm.nih.gov/28858412

Zobrazit plný text záznamu

Evaluation of the Efficacy and Tolerability of Combination Therapy With Candesartan Cilexetil and Amlodipine Besilate Compared With Candesartan Cilexetil Monotherapy and Amlodipine Besilate Monotherapy in Japanese Patients With Mild-to-Moderate Essential Hypertension: A Multicenter, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Autor: Hiromi Rakugi, Nobuo Totsuka, Yuko Miyata, Toshio Ogihara, Kiyofumi Sasai

Publikováno v: Clinical Therapeutics. 34:838-848

Blood pressure is reported to be insufficiently controlled in50% of patients with hypertension. Guidelines for the management of hypertension recommend using drugs with different mechanisms of action when1 agent is needed to achieve the blood pressur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea9c09b29271cab70d836f805105443a
https://doi.org/10.1016/j.clinthera.2012.02.015

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání